<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483674</url>
  </required_header>
  <id_info>
    <org_study_id>2020-000601-89</org_study_id>
    <nct_id>NCT04483674</nct_id>
  </id_info>
  <brief_title>Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection</brief_title>
  <acronym>BIC-PHI</acronym>
  <official_title>Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The porpouse of this study is to assess the eficacy of Bictegravir/FTC/TAF in patients with
      less of 100 days post HIV infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing informed consent, patients will undergo to a screening visit. If they meet
      the inclusion criteria and none of the exclusion will be included in this trial. Patients
      will take one tablet of Biktarvy at day for 48 weeks. Then the results will be compared with
      a cohort of 66 patiens treated with 2 nucleoside analogues and one integrase chain transfer
      inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portion of patients with a viral load&lt; 50 Copies at week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Portion of patients with rapid ART initiation who reached a VL&lt; 50 copies at 48 week in the intention to treat population determined by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Load at 4,8,12,24 y 48 weeks</measure>
    <time_frame>weeks 4,8,12,24,48</time_frame>
    <description>Determination by PCR of viral load at diferents week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portion of patients with &gt; 900 cells CD4+</measure>
    <time_frame>weeks 24 and 48</time_frame>
    <description>Proportion of patients with &gt;900 cells CD4+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days elapsed between diagnosis and bictegravir/FTC/TAF initiation</measure>
    <time_frame>week 48</time_frame>
    <description>Days elapsed between diagnosis and bictegravir/FTC/TAF initiation, day elapsed between first clinical visit and Bictegravir/FTC/TAF initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated with Bictegravir/FTC/TAF who reached a VL&lt;50 copies at 48 weeks in the intentio-to-treat (ITT) population</measure>
    <time_frame>week 48</time_frame>
    <description>Proportion of patients treated with Bictegravir/FTC/TAF who reached a VL&lt;50 copies at 48 weeks in the intentio-to-treat (ITT) population in comparison with other InSTI-, based ART regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE leading to discontinuation rate</measure>
    <time_frame>week 48</time_frame>
    <description>AE leading to discontinuation rate in comparison with other InSTI- based ATR regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4, CD4/CD8 ratio</measure>
    <time_frame>weeks 4,8,12,24,48</time_frame>
    <description>CD4, CD4/CD8 ratio at weeks 4,8,12,24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE rate</measure>
    <time_frame>week 48</time_frame>
    <description>AE rate (overall and AE leading to discontinuation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of required regimen changes</measure>
    <time_frame>week 48</time_frame>
    <description>Number of required regimen changes stratified by: adverse events/toxicity, virological failure, simplification, transmitted drugresistance (including polymorphisms for InSTIs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and satisfaction: questionnaire</measure>
    <time_frame>day 0, week 4 and 48</time_frame>
    <description>Quality of life and satisfaction evaluated through a CESTA questionay at 4 and 48 weeks (or at the end of study in case of early termination) of the study period, and Pittsburgh Sleep Quality Index (PSQI) at day 0, 4 week and 48 weeks (or at the end of study in case of early termination) of the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reservoir, inflammatory and immunological markers and fecal microbiome composition</measure>
    <time_frame>weeks 0,48</time_frame>
    <description>Viral reservoir, inflammatory and immunological markers and fecal microbiome composition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>HIV Primary Infection</condition>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will recive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide</intervention_name>
    <description>Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 incluiding:
complete physical examintaion
register concomitant medication
blood test
concomitant medications
assessment od adverse events
assessement of compliance
PSQI and CESTA questionnaire (week 4 and 48)
Recomendation in contraception methdos
Stool sample and pregnacy test urine (week 0 and 48)
The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL</description>
    <arm_group_label>Biktarvy</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 18-65 years

          -  ART naïve

          -  HIV infection of less than 100 days post-infection (documented 3 month previous
             negative serology or incomplete WB test with negative p31 band)

          -  Women of child-bearing potential must have a negative pregnancy test in serum before
             the inclusion in the study and agree to use highly effective contraceptive methods,
             including intrauterine device, bilateral tubal occlusion or a vasectomized partner.

        Exclusion Criteria:

          -  Known hypersensitivity to any drug included in Bictegravir/FTC/TAF regimen

          -  AST &gt;5 times UNL

          -  Creatinine Clearance &lt;30 mL/min/1.73m2

          -  Any end-stage organ disease

          -  Acute or chronic HCV co-infection

          -  Use of PrEP with Truvada® until 4 weeks before the onset of symptoms of PHI (risk of
             acquired-drug resistance to FCT or TDF).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Cruceta, MD</last_name>
    <phone>9322754000</phone>
    <phone_ext>4380</phone_ext>
    <email>acruceta@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose María Miró, MD</last_name>
    <email>jmmiro@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jose M Miró, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Ambrosioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Mallolas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonsoles Sanchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montserrat Plana</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Rovira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Hurtado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Alcamí</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV Primary Infection</keyword>
  <keyword>Biktarvy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

